Cantor Fitzgerald Reinstates Overweight on Arcus Biosciences, Maintains $46 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has reinstated Arcus Biosciences (NYSE:RCUS) with an Overweight rating and maintained a $46 price target.
July 12, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcus Biosciences has been reinstated with an Overweight rating by Cantor Fitzgerald, with a maintained price target of $46.
The reinstatement of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Arcus Biosciences. The maintained price target of $46 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100